IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v11y2020i1d10.1038_s41467-020-17648-w.html
   My bibliography  Save this article

Cyclic peptide FXII inhibitor provides safe anticoagulation in a thrombosis model and in artificial lungs

Author

Listed:
  • Jonas Wilbs

    (Ecole Polytechnique Fédérale de Lausanne (EPFL))

  • Xu-Dong Kong

    (Ecole Polytechnique Fédérale de Lausanne (EPFL))

  • Simon J. Middendorp

    (Ecole Polytechnique Fédérale de Lausanne (EPFL))

  • Raja Prince

    (Bern University Hospital, University of Bern
    University of Bern)

  • Alida Cooke

    (Carnegie Mellon University)

  • Caitlin T. Demarest

    (Carnegie Mellon University)

  • Mai M. Abdelhafez

    (University of Bern)

  • Kalliope Roberts

    (Carnegie Mellon University)

  • Nao Umei

    (Carnegie Mellon University)

  • Patrick Gonschorek

    (Ecole Polytechnique Fédérale de Lausanne (EPFL))

  • Christina Lamers

    (Ecole Polytechnique Fédérale de Lausanne (EPFL))

  • Kaycie Deyle

    (Ecole Polytechnique Fédérale de Lausanne (EPFL))

  • Robert Rieben

    (University of Bern)

  • Keith E. Cook

    (Carnegie Mellon University)

  • Anne Angelillo-Scherrer

    (Bern University Hospital, University of Bern
    University of Bern)

  • Christian Heinis

    (Ecole Polytechnique Fédérale de Lausanne (EPFL))

Abstract

Inhibiting thrombosis without generating bleeding risks is a major challenge in medicine. A promising solution may be the inhibition of coagulation factor XII (FXII), because its knock-out or inhibition in animals reduced thrombosis without causing abnormal bleeding. Herein, we have engineered a macrocyclic peptide inhibitor of activated FXII (FXIIa) with sub-nanomolar activity (Ki = 370 ± 40 pM) and a high stability (t1/2 > 5 days in plasma), allowing for the preclinical evaluation of a first synthetic FXIIa inhibitor. This 1899 Da molecule, termed FXII900, efficiently blocks FXIIa in mice, rabbits, and pigs. We found that it reduces ferric-chloride-induced experimental thrombosis in mice and suppresses blood coagulation in an extracorporeal membrane oxygenation (ECMO) setting in rabbits, all without increasing the bleeding risk. This shows that FXIIa activity is controllable in vivo with a synthetic inhibitor, and that the inhibitor FXII900 is a promising candidate for safe thromboprotection in acute medical conditions.

Suggested Citation

  • Jonas Wilbs & Xu-Dong Kong & Simon J. Middendorp & Raja Prince & Alida Cooke & Caitlin T. Demarest & Mai M. Abdelhafez & Kalliope Roberts & Nao Umei & Patrick Gonschorek & Christina Lamers & Kaycie De, 2020. "Cyclic peptide FXII inhibitor provides safe anticoagulation in a thrombosis model and in artificial lungs," Nature Communications, Nature, vol. 11(1), pages 1-13, December.
    • Handle: RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-17648-w
    DOI: 10.1038/s41467-020-17648-w
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-020-17648-w
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-020-17648-w?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Pengfei Xu & Yingjie Zhang & Junyan Guo & Huihui Li & Sandra Konrath & Peng Zhou & Liming Cai & Haojie Rao & Hong Chen & Jian Lin & Zhao Cui & Bingyang Ji & Jianwei Wang & Nailin Li & De-Pei Liu & Tho, 2024. "A single-domain antibody targeting factor XII inhibits both thrombosis and inflammation," Nature Communications, Nature, vol. 15(1), pages 1-14, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-17648-w. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.